Q32 Bio Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on May 19, 2025, indicating that the company is no longer in compliance with the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The company's recent financial report showed a stockholders' equity deficit of approximately $4.0 million. Additionally, Q32 Bio failed to meet alternative criteria, such as a market value of listed securities of $35.0 million or net income from continuing operations of $0.5 million. This situation arose partly due to the accounting impact of re-acquiring bempikibart from Amgen Inc. Q32 Bio now has 45 days to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension of up to 180 days for Q32 Bio to meet the listing requirements. Meanwhile, the company's stock will continue trading on Nasdaq under the symbol "QTTB."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.